Clinical Studies

Here are clinical studies provided by scientist, researchers, doctors, and medical journals with appropriate research and/or testing of various Probiotic strains specifically for feminine health.

We wanted to provide information to you as an user with facts by proving some of our claims with legitimacy.

Clinical Efficacy Trials are a set of procedures in product research and development that are conducted to test the product's intended purpose in order to substantiate those all-important claims that appear on your packaging or in your advertisements. 

Ingestion of Yogurt Containing Lactobacillus acidophilusas Prophylaxis for Candidal Vaginitis


Eileen Hilton, MD; Henry D. Isenberg, PhD; Phyllis Alperstein, DMT; Kenneth France, MS; and Michael T. Borenstein, PhD
Ann Intern Med. 1992;116(5):353-357. doi:10.7326/0003-4819-116-5-353
  • Objective: To assess whether daily ingestion of yogurt containing Lactobacillus acidophilus prevents vulvovaginal candidal infections.

Design: Crossover trial for at least 1 year during which patients were examined for candidal infections and colonizations while receiving either a yogurt-free or a yogurt-containing diet. Patients served as their own controls.

Setting: Ambulatory infectious disease center in a teaching hospital providing tertiary care.

Patients: Thirty-three women with recurrent candidal vaginitis were eligible after recruitment from community practices and clinics and through advertising. Twelve patients were eliminated for protocol violations. Of the remaining 21 patients, 8 who were assigned to the yogurt arm initially refused to enter the control phase 6 months later. Thus, 13 patients completed the protocol.

Interventions: Women ate yogurt for 6 months of the study period.

Measurements: Colonization of lactobacilli and Candida in the vagina and rectum; candidal infections of the vagina.

Main Results: Thirty-three eligible patients were studied. A threefold decrease in infections was seen when patients consumed yogurt containing Lactobacillus acidophilus. The mean (± SD) number of infections per 6 months was 2.54 ± 1.66 in the control arm and 0.38 ± 0.51 per 6 months in the yogurt arm (P = 0.001). Candidal colonization decreased from a mean of 3.23 ± 2.17 per 6 months in the control arm to 0.84 ± 0.90 per 6 months in the yogurt arm (P = 0.001).

Conclusion: Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.


2001 Feb;73(2 Suppl):437S-443S.

Probiotic agents to protect the urogenital tract against infection.


The urogenital microflora of a healthy woman comprises approximately 50 species of organisms, which differ in composition according to reproductive stages and exposure to several factors, including antibiotics and spermicides. Infections are very common with > 300 million cases of urinary tract infections, bacterial vaginosis, and yeast vaginitis worldwide per annum. At the time of infection in the bladder and vagina, the urogenital flora is often dominated by the infecting pathogens, in contrast with healthy phases when indigenous organisms dominate. Premenopausal women have a flora of mostly lactobacilli, and certain properties of these strains, including adhesive ability and production of acids, bacteriocins, hydrogen peroxide, and biosurfactants, appear important in conferring protection to the host. Efforts to artificially restore an unbalanced flora with the use of probiotics have met with mixed results but research aimed at selecting scientifically based strains could well provide a reliable alternative treatment and preventive regimen to antibiotics in the future.

[PubMed - indexed for MEDLINE]


2001 Feb 1;183(3):485-91. Epub 2000 Dec 29.

Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells.


To gain insight into the mechanisms by which Lactobacillus blocks the adherence of uropathogens to vaginal epithelial cells and inhibits their growth, 15 Lactobacillus strains and 22 uropathogens were studied. Lactobacilli from hemagglutination group III, identified as Lactobacillus crispatus, showed greater capacity to block uropathogen adherence than those from hemagglutination groups II and I (61.9%, 49.5%, and 52.6% of blockage, respectively). Pseudomonas aeruginosa PA5 and Klebsiella pneumoniae KP7 were the uropathogens most susceptible to blockage, and Staphylococcus aureus SA11 and Proteus mirabilis PM1 were the most resistant. Lactobacillus inhibited uropathogen growth better in liquid assays; the 3 Lactobacillus groups showed similar inhibitory power (72.3%, 71.9%, and 74.2% of light transmittance). P. aeruginosa PA5 was the most inhibited, and Enterococcus species E15 was the least inhibited. There is considerable variation among Lactobacillus strains regarding their adherence to uroepithelium, blockage of uropathogen attachment, and inhibition of uropathogen growth. Although these properties are independent, they may coincide and therefore allow for these strains to balance the vaginal ecosystem and to make them useful as probiotics.

[PubMed - indexed for MEDLINE]